Drug Profile


Alternative Names: OPC 18790; Torborinone

Latest Information Update: 04 Sep 2009

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Cardiotonics; Quinolones; Vasodilators
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 28 Jan 2003 A clinical study has been added to the pharmacokinetics section
  • 04 Sep 1998 A preclinical study has been added to the Heart Failure pharmacodynamics section
  • 06 Jul 1998 A clinical study has been added to the Heart failure pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top